Insider Buying: Immune Design Corp. (IMDZ) Major Shareholder Acquires $97,000.00 in Stock
Immune Design Corp. (NASDAQ:IMDZ) major shareholder Leo Guthart purchased 10,000 shares of the business’s stock in a transaction on Monday, September 18th. The shares were bought at an average cost of $9.70 per share, for a total transaction of $97,000.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.
Shares of Immune Design Corp. (NASDAQ IMDZ) opened at 10.50 on Monday. Immune Design Corp. has a 12 month low of $4.50 and a 12 month high of $13.05. The firm’s 50-day moving average price is $9.58 and its 200 day moving average price is $8.01. The firm’s market capitalization is $269.00 million.
Immune Design Corp. (NASDAQ:IMDZ) last announced its earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.54) EPS for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.11. Immune Design Corp. had a negative net margin of 324.33% and a negative return on equity of 59.14%. The business had revenue of $0.73 million during the quarter, compared to analysts’ expectations of $1.50 million. Analysts anticipate that Immune Design Corp. will post ($2.34) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Insider Buying: Immune Design Corp. (IMDZ) Major Shareholder Acquires $97,000.00 in Stock” was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright law. The correct version of this report can be read at https://www.thecerbatgem.com/2017/09/25/insider-buying-immune-design-corp-imdz-major-shareholder-acquires-97000-00-in-stock.html.
Several brokerages have weighed in on IMDZ. ValuEngine raised Immune Design Corp. from a “sell” rating to a “hold” rating in a research report on Friday, August 11th. BidaskClub downgraded Immune Design Corp. from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 5th. Royal Bank Of Canada began coverage on Immune Design Corp. in a research report on Thursday, September 14th. They set an “outperform” rating and a $20.00 price target on the stock. Jefferies Group LLC reaffirmed a “buy” rating and set a $18.00 price target on shares of Immune Design Corp. in a research report on Wednesday, June 28th. Finally, Cowen and Company reaffirmed a “buy” rating on shares of Immune Design Corp. in a research report on Tuesday, June 6th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Immune Design Corp. presently has an average rating of “Buy” and an average target price of $16.33.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. State of Wisconsin Investment Board purchased a new position in Immune Design Corp. during the second quarter worth about $117,000. Alliancebernstein L.P. purchased a new position in Immune Design Corp. during the second quarter worth about $118,000. Bank of America Corp DE raised its holdings in Immune Design Corp. by 123.3% during the first quarter. Bank of America Corp DE now owns 15,246 shares of the biotechnology company’s stock worth $104,000 after purchasing an additional 8,418 shares in the last quarter. Virtu KCG Holdings LLC purchased a new position in Immune Design Corp. during the second quarter worth about $153,000. Finally, Dimensional Fund Advisors LP raised its holdings in Immune Design Corp. by 9.3% during the second quarter. Dimensional Fund Advisors LP now owns 18,896 shares of the biotechnology company’s stock worth $184,000 after purchasing an additional 1,600 shares in the last quarter. 51.46% of the stock is owned by hedge funds and other institutional investors.
About Immune Design Corp.
Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company has engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer.
Receive News & Stock Ratings for Immune Design Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design Corp. and related stocks with our FREE daily email newsletter.